Specific causes of death were analyzed for 10,908 participants in the Hypertension Detection and Follow-up Program, to explore possible explanations for the observed excess S3 -year mortality from all causes in hypertensives with low body mass. Although the cardiovascular mortality rate among men in the lowest decile of body mass (body mass index 21.96 or less) was 50% higher than that of men in the median class (body mass index 26.4-28.8), death rate for noncardiovascular deaths was more than 2Vi times higher in men with lean versus median body mass. The pattern was similar among women. Among noncardiovascular causes, striking differences in mortality rates between lean hypertensives and those of average body mass were observed for cirrhotic death (relative risk of 12+ in men and 11+ in women), for nonmalignant respiratory disease in men (relative risk of 7+), for violent death (both sexes), and for malignant neoplasms in men. Prevalence of smoking was almost twice as high in the lowest compared with the median body mass group; among the lean, excess deaths, particularly noncardiovascular deaths, were concentrated among smokers. Thus, male smokers in the lowest decile of body mass constituted only 3% of the study population, but contributed 8% of all deaths, 11% of all noncardiovascular deaths, and 22% of all cirrhotic deaths. A larger proportion of deaths occurred early in follow-up in the lean versus other hypertensives, suggesting occult disease among the lean at baseline. There was no evidence that more severe or treatment-resistant hypertension was present in or could explain excess mortality among the hypertensives with low body mass. The inference from the findings is not that overweight is protective for hypertensives nor that excess risk is due to leanness per se. Rather, a reasonable hypothesis, particularly from findings on specific causes of death, is that excess mortality in lean hypertensives is due to deleterious lifestyles, particularly smoking and excess alcohol intake, contributing to both leanness and risk of death. (Hypertension 1991;17:553-564)
S everal prospective studies of persons with hypertension have investigated the relation of body mass to prognosis. 1 " 9 Most have reported excess mortality in hypertensives with low body mass or mass below the average in the group studied.
| -3 ' 5 -7 ' 9 In some, there was an inverse associ- ) were found to have a slightly higher than average mortality rate.
Mortality surveillance of HDFP participants continued after the trial was terminated, and data are available for 8.3 years of follow-up from baseline. 11 The present report further analyzes the data from HDFP to examine the following: Do data on 8.3 years of follow-up confirm the 5-year findings of excess mortality in those with lowest body mass? Is this excess mortality more prominent in the early years of follow-up? Does excess mortality in specific causes of death suggest any possible reasons for the higher mortality rates observed in the lean hypertensives? Could any traits be identified at baseline to explain the observation? Was hypertension more severe or less responsive to treatment in the hypertensives with lower BMI compared with others and could this explain the excess mortality?
Methods
The design and methods of HDFP, as well as overall 5-year mortality results, have been extensively reported 10, 12-15 They are summarized here. The study was a randomized controlled clinical trial to determine effectiveness of vigorous, systematic antihypertensive therapy in reducing all-cause mortality in adults who were identified as hypertensive from samples of the general population. The only exclusions from the study were persons institutionalized or permanently bedridden and thus unable to attend the program.
Study Participants
Overall, approximately 159,000 men and women aged 30-69 years were screened in [1973] [1974] in defined populations, with as complete case finding as possible. 1617 In the first screening (at home in 13 centers and at workplaces in one center), each person with fifth phase diastolic pressure of 95 mm Hg or more (average of second and third readings, seated, with use of a standard mercury manometer and appropriate size cuff) was invited to a second visit at the local study clinical center. At that visit, diastolic pressure of 90 mm Hg or more (average of two readings with a random zero manometer) 18 qualified the individual for admission to the trial. Altogether, 10,940 persons were enrolled and randomly assigned to one of two treatment groups -stepped care, treated vigorously at the 14 clinical centers to reach a diastolic goal pressure of 80-90 mm Hg (depending on entry level and prior treatment), or referred care, the control group treated by personal physicians according to usual community practice. A detailed medical history and extensive medical examination were completed at two baseline clinic visits. Signed informed consent was obtained from all participants.
End Points
Participants were followed during the trial for a minimum of 5 years. The primary end point was all-cause mortality, and vital status was determined for 99.5% of all participants at the end of the trial. Specific underlying cause of death was determined by nosologists, based on the death certificate collected for each decedent. 19 Nosologists were blinded as to study group assignment of the decedents and coded the underlying cause of death according to the 8th Revision of the International Classification of Diseases, adapted for use in the United States (ICDA). 20 As previously reported, overall trial results showed that the vigorously treated stepped care group experienced an all-cause 5-year mortality rate significantly lower (-17%) than the referred care group. 1314 The present report examines all causes and specific causes of mortality in 8.3 years, in classes of body mass index, following the same procedures in coding causes of death as for the 5-year assessment. The methodology for posttrial vital status follow-up has been reported. 11 
Body Mass Index
In this analysis, all participants, stepped care and referred care combined, were grouped according to baseline BMI. Height and weight were measured (without shoes, coat, or jacket) at baseline and recorded to the nearest inch and pound (later transformed into kilograms and meters). 21 
Statistical Methods
Body mass index was available for 10,908 of the 10,940 randomized individuals. Quintiles of BMI were examined that would permit assessing mortality experience of definitely lean as well as markedly overweight participants, in comparison with those of average BMI (central BMI quintile). Thus, body mass class limits were selected to approximate the lowest and highest 10% of the BMI distribution. In the remainder of this report, reference to the upper and lower deciles of BMI relates to the class limits found in the whole study population. For any given subgroup, the actual percentage in a particular BMI class may vary somewhat from that of the whole distribution (e.g., the lowest decile included 8.2% of men and 12.1% of women . Where the numbers of deaths were sufficient to produce stable rates, mortality patterns for the lowest and highest 5% of BMI (20.51 kg/m 2 or less and 39.07 kg/m 2 or more, respectively) are also reported in the text. In multiple logistic regression analyses including the whole cohort, BMI is treated as a continuous variable.
Mortality rates were directly adjusted for differences among body mass classes in age, race, and sex. 22 To provide an adjusted rate comparable across all stratification variables, 12 crude rates -for the four race-sex groups and three age groups (30-49, 50-59, and 60-69 years) -were applied to corresponding cells of a standard population consisting of all HDFP trial participants. When stratification involved age, race, or sex, the number of crude rates was reduced accordingly. Comparisons of death rates were made between BMI classes at upper and lower ends of the body mass distribution and the class containing median study-wide BMI. Relative mortality risks and their 95% confidence limits were calculated, using a first-order Taylor series approximation method 23 (see Appendix). Where the confidence interval included 1.00, relative risk comparing BMI classes did not differ significantly (at the 5% level) from 1.00. Because the subgroup analyses presented here involve multiple comparisons, there is for any individual comparison a probability greater than 0.05 that exclusion of 1.00 in a confidence interval could occur by chance alone. No adjustment for multiple comparisons was made. Logistic regression analyses were performed to test for quadratic relations between BMI and mortality. Polychotomous logistic regression analysis was performed to compare coefficients for different outcomes. Variables included in the analyses are described below.
Results

All-Cause Mortality
All participants. The association between body mass and all-cause 8.3-year mortality for all randomized participants with body mass data is reported in Table 1 . Highest death rate was observed in those with lowest BMI (24.9 per 100 for the lowest 5% and 21.7 per 100 for the lowest decile of body mass). Death rate in the middle quintile (12.2 per 100) was approximately one half that in the lowest 5% of body mass.
At the upper end of the body mass range, mortality rate in the top BMI decile (12.1 per 100) was similar to that in the median BMI class, but death rate in the highest 5% of BMI was about 22% greater than in the median body mass group.
Logistic regression analysis confirmed the existence of a significant quadratic relation between body mass index and 8.3-year mortality, that is, all-cause mortality rates, adjusted for sex, race, and age, were significantly higher at both the lower and upper end of the BMI distribution than at median body mass. The estimated coefficients for both the linear and quadratic terms for BMI were significant (/><0.001).
Men and women. Table 2 presents findings on all-cause mortality, for men and women separately, for the upper and lower deciles versus the median of the study-wide BMI distribution. The adverse association between low body mass and mortality was seen in both sexes, with relative risk 1.96 for men and 1.41 for women, for the lowest decile compared with median BMI class. Relative risks for the lowest 5% of BMI were 2.20 and 1.80, for men and women respectively (i.e., somewhat greater than for the lowest 10%). About two thirds of the deaths in the lowest decile were in the lowest 5% of BMI.
For men in the highest BMI decile, all-cause mortality rate was similar to that of men in the median group, but those in the highest 5% of body mass had a death rate 36% higher than the median class. Women in the upper BMI decile had a slightly higher rate than those with median BMI mass (relative risk, 1.11).
In multiple logistic regression analysis for all men in the cohort, a highly significant quadratic relation was shown (p<0.0001); this relation was also highly significant for women (p<0.0001), but weaker, with the magnitude of the quadratic coefficient about one half that of men.
Cardiovascular and Noncardiovascular Mortality
Men. Although mortality rate from cardiovascular causes was more than 50% higher in the lowest decile than in the median group (relative risk, 1.57), the excess was more notable for noncardiovascular causes (Table 2) . For all noncardiovascular causes combined, relative risk was 2.59 for the lowest decile versus median BMI and was even greater (3.30) for the lowest 5% of body mass. In men in the lowest BMI decile, noncardiovascular deaths constituted 58% of all deaths, whereas for men with median BMI the majority of deaths (60%) were from cardiovascular disease.
As for men in the highest BMI decile, they had a higher death rate than the median BMI group from all cardiovascular causes, but not from noncardiovascular disease deaths. Neither difference was significant. Unlike the leanest men, in whom noncardiovascular causes predominated, more than two thirds of deaths in the overweight men were from cardiovascular disease.
Women. The pattern of excess mortality seen in the lean hypertensive men was similar in women ( Table  2) . Relative risk for the lowest decile was greater for noncardiovascular than cardiovascular causes of death (1.66 for noncardiovascular causes and 1.16 for cardiovascular causes). Difference from the median group was significant for noncardiovascular causes but not for cardiovascular causes. As among men, more than half the deaths among the lean women were from noncardiovascular causes, whereas for both median BMI and overweight women, cardiovascular disease deaths predominated. For overweight women, death rates for all cardiovascular and noncardiovascular causes were either similar to or only slightly higher than for the median BMI class.
Overall pattern, men and women combined. In addition to the above comparisons of the extremes of BMI versus median BMI, multiple polychotomous logistic regression analysis was performed involving all 10,908 study participants. The aims were to determine whether the observed relation of BMI to mortality was independent of other known risk factors, was significantly stronger for noncardiovascular than cardiovascular causes, and included significant excess mortality both for lower and higher body mass. Three outcomes were tested -death from cardiovascular causes, death from noncardiovascular causes, or 8.3-year survival. The analysis yielded significant linear and quadratic coefficient estimates relating body mass to both cardiovascular and noncardiovascular death, independent of other factors examined. In addition to BMI and squared BMI, other variables included were sex, race, age, BMI interaction with sex and race, current cigarette smoking, and ex-smoking. The relation of BMI was more pronounced for noncardiovascular deaths than for cardiovascular deaths. The linear BMI coefficient for noncardiovascular was 1.57 times that for cardiovascular deaths (marginally significant, p =0.08), and the quadratic BMI coefficient 1.31 times greater (NS). All four coefficients differed significantly from zero (/xO.OOOl).
Deaths Probably Related to Alcohol Use
The finding that excess risk for lean hypertensives was concentrated in noncardiovascular causes of death led to examination of specific noncardiovascular causes for possible determinants of the overall pattern observed. Of particular interest were causes of death that might relate to lifestyle traits more common in persons of lower body mass. Among men, death from hepatic cirrhosis -a cause of death very strongly related to excess alcohol intake -had the highest relative risk for those with lean versus median body mass (relative risk of 12.45 for the lowest 10% of BMI) ( Table 3) . Relative risk for cirrhotic death was also very high for lean women (11.2). Although total number of deaths for which death certificates indicated cirrhosis was not large, lean hypertensives had a disproportionate share: there were 37 deaths due to cirrhosis in the entire study, and low BMI hypertensive men and women, who constituted only 10% of all participants, accounted for 16 of these deaths-43%. Deaths from violent causes (accidents, homicides, suicides) are also strongly associated with alcohol use. For these causes, relative risk for men in the bottom BMI decile was more than 3.00 compared with those with median body mass (Table 3) . For lean women, relative risk for these deaths was even higher (5.08). However, for both sexes overall numbers of deaths from this set of causes were few and relative risks were not significant across BMI groups.
Deaths from nonmalignant respiratory disease also showed a high relative risk for lean men (7.38 for the lowest decile) and was also significantly higher for malignant neoplastic death. Both these causes of death are related to smoking (see below) and, in the case of some neoplasms, may also be related to alcohol use.
Smoking-Related Deaths
This excess of deaths in lean hypertensive men from nonmalignant respiratory diseases and malignant neoplasms suggested that higher prevalence of smoking in lean hypertensives might also help explain the differential mortality observed in the BMI groups. Baseline prevalence of smoking was 1.65 times as high in the lowest BMI decile as in those with median body mass (59.7% versus 36.2%, p<0.0001) ( Table 4) . Heavy smoking (more than a pack a day) was also higher in the lean. Excess prevalence of smoking among the lean hypertensives was observed in all four sex-race groups. Among the lean, smoking was higher in blacks than in whites and in men than women. Because both smoking prevalence and number of events was greater in men than women, the comparison of death rates according to smoking status in Table 5 is presented for men only.
For current smokers, men in the lowest 10% of body mass had higher death rates than the median group for both major causes of death, with relative risks of 1.23 for cardiovascular deaths and 3.07 for all noncardiovascular deaths. For respiratory death, relative risk was more than 9 and, for cirrhotic death, more than 11. These male smokers in the lowest decile of body mass constituted only 3% of the whole study population but contributed more than 8% of all deaths, 6% of cardiovascular deaths, 11% of noncardiovascular deaths, 10% of neoplastic deaths, 24% of respiratory deaths, and 22% of all cirrhosis deaths in the entire study. Of the 30 neoplastic deaths in these lean male smokers, 11 were from lung cancer, clearly related to smoking, and 12 additional deaths were from cancers of the mouth, pharynx, and digestive systems, possibly related to both smoking and high alcohol intake. It is a common observation that heavy 25 Among the nine cirrhosis deaths observed in men with low BMI, eight were in smokers, none among ex-smokers, and one was in a person who never smoked.
In lean ex-smokers and those who never smoked, there were also relative risks greater than 1.00 for all causes, for cardiovascular and noncardiovascular causes, but denominators and numbers of events were small for lean nonsmoking men and, for these substrata, differences from mortality rates of those of median body mass were not significant.
Excess Risk in Lean Hypertensives in Different Time Periods
Analyses were carried out for separate time periods in follow-up to determine whether excess mortality in lean hypertensives was more prominent in early years. If relative risk was greatest early in the trial, this could suggest either higher prevalence of prior disease in the lean or higher risk of early mortality because of greater frequency in that group of deleterious lifestyles. In fact, highest relative mortality risk was found in the first 2 years of follow-up in the leanest decile versus median BMI class (Table 6) . For all causes, relative risk for the lean was 2.92 in the first 2 years, 1.90 in years 2+ to 5, and 1.58 in years 5+ to 8.3. The largest contrast across the periods was in noncardiovascular causes of death where mortality was 4.58 times greater in the lean than the median BMI group in the first 2 years versus 1.91 times greater in years 5+ to 8.3. Annual absolute excess all-cause mortality among the lean compared with median BMI was also greater in the early years of follow-up.
For all causes, 27% of all deaths in 8.3 years occurred in the first 2 years among the leanest decile, compared with 16% of all 8.3-year deaths in that early period for the median BMI group. For both cardiovascular and noncardiovascular causes as well, a greater proportion of deaths occurred early in the leanest than in the median class.
Mortality Patterns by Race, Age, and Treatment Group
Race. Excess mortality for lean hypertensives was seen in both black and white HDFP participants. Although absolute death rate in lean blacks was higher than in lean whites for all major causes (e.g., 27.6 per 100 for all-cause mortality in blacks versus 17.1 in whites), relative risks for lean compared with median BMI class were similar in the two races (1.85 for blacks and 1.64 for whites). For both races, relative risks in the lean were greater for noncardiovascular than cardiovascular mortality; however, the proportion of deaths due to noncardiovascular causes was somewhat greater in lean blacks (60%) than in whites (47%). Both races had the greatest excess relative risk among the lean in deaths related to smoking and alcohol (cirrhosis, violence and accidents, respiratory disease, and neoplasms). In logistic regression analyses, significant linear and quadratic relations were seen between body mass and mortality for both race groups.
Age. Excess mortality in lean hypertensives in HDFP was observed in the age strata 30-49 and 50-69 years. Relative risk of all-cause mortality in the lowest decile versus median BMI was 2.22 in the younger group (11.0 versus 4.6 deaths per 100). In the older subgroup, relative risk was slightly lower (2.03), but with higher mortality rates, absolute difference between the two BMI classes was marked (30.4 versus 18.1 deaths per 100). In both age groups, there was a U-shaped curve for all-cause mortality, that is, those with both low and high body mass had higher death rates than those with median body mass, but rates in the high BMI groups were below those in the lowest BMI class.
Stepped care and referred care. In both randomized study groups, lean hypertensives had higher all-cause mortality than those in the median BMI groups, and the relative risks (lean versus median) were similar for stepped and referred care (1.85 and 1.81, respectively). For stepped care and referred care, relative risk for noncardiovascular deaths was greater than for cardiovascular deaths, with alcohol and smokingrelated causes notable in both groups.
Severity of Hypertension and Treatment Response in Different Body Mass Index Classes
Several indices of severity of hypertension were examined in the BMI groups to determine if lean hypertensives had more severe hypertension ( Table  7) . The percentage on medication at entry into the study was used as one indication of severity. All persons enrolled in HDFP had hypertensive pressures at entry; if individuals had such pressures despite medication, this might suggest severe hypertension or resistance to treatment. In addition, in 1973-1974 it was more likely that drug treatment would be prescribed for severe rather than mild hypertension. The percentage initially on treatment was, in fact, lower in the lowest decile than in the median or high BMI groups. Positive family history of hypertension also was not more frequent in the lean (Table 7) .
Average entry blood pressure was somewhat higher in the lean than median BMI class (as was entry pressure in the highest BMI decile). The percentage defined as "mild" (i.e., diastolic pressure 90-104 mm Hg without medication) was also somewhat lower in the lean than the median BMI group, and the percentage with cardiovascular end organ damage at entry was slightly higher in the lean. Thus, on the indexes examined, findings were mixed. Although there were some differences between BMI groups suggesting more severe hypertension in the lowest BMI group, the pattern was Rates per 100 deaths are adjusted for age, sex, and race. Denominators for rates per 100 deaths in 2+ to 5-year and 5+ to 8.3-year categories exclude deaths in previous period. BMI, body mass index (kg/m 2 ); CL, confidence limits; RR, relative risk; CVD, cardiovascular diseases.
not consistent or strong. It was, in fact, the highest BMI class that showed largest differences compared with the median group on almost all selected indexes of severity.
In analyses of response to treatment, only the stepped care participants of HDFP were included since a common study protocol provided vigorous treatment for all in stepped care to a normal goal pressure, whereas for referred care individuals, approach to treatment and control varied according to local practice. In regard to reduction in blood pressure during the trial, all BMI groups in stepped care had virtually the same fall in diastolic pressure (16-17 mm Hg), and fall in systolic pressure was slightly greater for the lean hypertensives (29 mm Hg) compared with a fall of 26 mm Hg in the other BMI groups ( Table 7) . As to percent achieving goal pressure, there was little difference between the lean and median BMI groups. Thus, on these several indexes of response to treatment, there was no indication that the elevated blood pressure of lean hypertensives was harder to control. At goal DBP at year 5 BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure.
•Not on antihypertensive medication at trial entry. tMajor left ventricular hypertrophy, history of myocardial infarction, Q-QS 1.1-1.2 electrocardiographic abnormalities, history or physical evidence of stroke, elevated serum creatinine (£1.7 mg/dl), intermittent claudication, angina pectoris, or possible myocardial infarction by Rose Questionnaire, and evidence of ischemia on electrocardiogram.
JGoal diastolic blood pressure is defined in Methods.
by guest on July 12, 2017 http://hyper.ahajournals.org/ Downloaded from Discussion A key finding in this analysis of HDFP mortality data was the large relative risk of death from noncardiovascular diseases in lean hypertensive men and women compared with those of median body mass. For men in the lowest decile of BMI, death rate from all noncardiovascular causes was more than two and a half times greater than for those in the median group. Neoplastic death rate was almost twice as high in these lean men versus men in the median BMI class: one third of the 36 neoplastic deaths were from lung cancer and another third from cancers of the mouth, pharynx, and digestive systems. Other respiratory deaths were seven times more common and death from violence and accidents three times as common in the leanest 10% of men. Death from cirrhosis was more than 12 times that of men in the median BMI group. For hypertensive women with the lowest BMI, the rate of all noncardiovascular deaths was 1.67 times greater than that of the middle BMI group. Although the number of deaths from cirrhosis and violence or accidents were few among women, mortality rates for these causes were markedly higher in the lean, significantly so for cirrhotic death, with relative risk of 11.18. As among men, although there was an excess of deaths from all causes and from cardiovascular diseases among the lean, largest relative risks were for several noncardiovascular diseases.
Most other investigations of excess mortality in lean hypertensives have dealt only with death from all causes or with fatal and nonfatal cardiovascular disease. 8 Although study of these end points has served to raise the issue of increased risk among the lean, a focus on such end points is limited in its ability to examine possible causes for the observed excess. Even in those studies where noncardiovascular death was considered, specific noncardiovascular causes (e.g., cirrhosis, specific neoplasms, violence, and accident) were not explored and no reasons for adverse outcome in lean hypertensives could be drawn from the data, except possibly leanness itself or a hypothesized "protective" effect of obesity. Given that obesity is a well-established risk factor for development of hypertension, it seems implausible that once hypertension sets in, obesity becomes a beneficial attribute. In fact, the HDFP data presented here on excess risk among the overweight do not support such an explanation. If men and women become hypertensive despite being lean, this suggests that other powerful causal factors have played an important role in development of the disease and that these factors add to overall mortality risk.
The HDFP findings on specific causes of death are consistent with the hypothesis that the excess mortality in lean hypertensives arises not from leanness per se, but from factors related both to their leanness and to risk of death, particularly such lifestyle factors as cigarette smoking and heavy alcohol intake. 25 ' 26 Such factors, while they increase risk also for cardiovascular mortality, markedly increase risk of death from several noncardiovascular causes, as observed here. In this population-based hypertensive cohort, smoking was almost twice as frequent in those with lean compared with median BMI and a disproportionate number of the excess deaths in the lean occurred in smokers. Lean male smokers, although constituting only 3% of the study population, contributed 8% of all deaths, 11% of noncardiovascular deaths, and 22% of cirrhosis deaths. The causes of death associated both with smoking and high alcohol intake were much more common in the lean hypertensives than in other BMI classes. It is reasonable to suggest that alcohol intake and the associated lifestyle trait of cigarette smoking are major contributors to the excess mortality in lean hypertensives. This inference needs additional investigation; the present study is limited in its ability to test this inference further since no direct data on alcohol intake were collected, although the data on cigarette smoking support the inference on lifestyle and excess risk in lean hypertensives.
Further support to the likelihood that excess death in the lean is not from "leanness" comes from the data on the pattern of this excess over time. If it were leanness as such that was etiologically responsible for the excess, it is likely it would be manifest in a similar way throughout the 8.3 years of follow-up. Certainly such major established cardiovascular risk factors as smoking, hypercholesterolemia, and hypertension continue to have unfavorable impact over many years of follow-up. In this HDFP study, both relative and absolute risk for all-cause mortality in the lean were greatest in the first 2 years. For noncardiovascular deaths, relative risk for the lean versus median BMI was almost three times as high in the first 2 years as in years 6-8.3 . This suggests that the excess deaths observed in those with lower BMI reflected special characteristics of such hypertensives, including occult disease, that affected both weight and mortality risk, especially in the initial years of follow-up.
Past studies of outcome for hypertensives in different body mass classes have varied considerably in their definitions of leanness and obesity. Menotti et al 7 noted that shifting the cut point in comparison of mortality in lean versus others in the rural Italian cohorts of the Seven Countries Study changed relative risk for all-cause mortality in the lean from 1.15 to 0.93. Several studies divided their samples at the median body mass and compared the lower and upper half of the distribution. Such a comparison may obscure the actual relations for two reasons: first, excess mortality may be concentrated in the small extremes of leanness and this excess is diluted by the larger remainder of those below the median (particularly if the median is high). It may be that it is precisely in the lowest body mass group that there is a preponderance of those lifestyle characteristics contributing strongly to excess mortality. Secondly, if there is a U-shaped or similar relation between body mass and outcome, particularly for some specific causes of death, a simple dichotomy will obscure the true picture.
Two types of comparisons have been made in previous studies on lean hypertensives. One comparison is among hypertensives, across classes of BMI (as in the present HDFP study). This yields a relative risk based on body mass among hypertensive individuals. If specific causes of death are examined, such relative risks may provide etiologic clues to help explain the differences observed. Another comparison made in several studies is mortality of hypertensives versus normotensives in different body mass classes. However, this latter comparison depends on trends in two sets of rates, those of hypertensives and those of normotensives. Even if the death rate among hypertensives does not change across body mass classes, should the death rate increase among normotensives as body mass increases (as seen in several studies), then relative risk of hypertensives versus normotensives would be less for obese than lean hypertensives. In fact, this would not demonstrate a protective effect of obesity in hypertensives, but rather a deleterious effect of obesity in normotensives. It would still be necessary to compare death rates among hypertensives to determine the relation of body mass to outcome in hypertensives and to examine this for specific causes of death to understand possible factors underlying this relation.
Findings in the Australian National Blood Pressure Study 1 illustrate the strong relation between lifestyle factors and outcome across different body mass classes. For nonsmokers, there was only a small gradient of risk of fatal and nonfatal cardiovascular events across five classes of body mass index. But among smokers, there was a marked excess of events in lean hypertensives, particularly in the placebo group, in both men and women. Although HDFP found an excess of death in lean hypertensives even among nonsmokers, this excess was markedly greater in smokers, so that for both studies, smoking appears to be a major factor related to outcome, particularly in the lean hypertensives.
The issues raised by excess mortality observed in a large number of studies comparing lean versus other hypertensives are important ones for public health and medical care. The data do not support any reversal of recommendations that overweight hypertensives should control obesity to lower pressure as well as reduce additional risk associated with obesity (e.g., obesity-related hyperlipidemia and hyperuricemia). Several studies have already demonstrated that blood pressure can be lowered with reduced weight, either as a single intervention or in combination with reduction of other risk factors tending to increase pressure (e.g., excess use of salt and alcohol). 27 -31 Nor do the data justify any suggestion that lean hypertensives should gain weight. The data do pose the need for further study of the reasons for the excess mortality observed in lean hypertensives, particularly study of specific causes of death and of lifestyle likely related to such causes. The findings in HDFP indicated that excess alcohol intake and smoking were important factors contributing to excess risk, particularly in lean hypertensives. Intervention to change such factors should be an important part of hypertensive treatment to reduce unnecessary risk.
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Why do lean hypertensives have higher mortality rates than other hypertensives?
